[Expression of Estrogen Receptor-Related Receptor Alpha and Estrogen Receptor Alpha in Endometrial Carcinoma and the Primary Investigation of Their Clinical Significance].

Min Gao,Li-hui Wei,Peng-ming Sun,Dan Zhao,Xiao-ping Li
DOI: https://doi.org/10.3321/j.issn:1671-167x.2006.05.004
2006-01-01
Abstract:OBJECTIVE To explore the roles of estrogen receptor-related receptor (ERR) alpha and estrogen receptor alpha in endometrial carcinoma and their clinical values. METHODS Thirty-five cases of endometrial carcinoma were examined by immunohistochemistry. Clinicopathologic features including FIGO stage, histological grade, myometrial invasion and nodal metastasis were reviewed. RESULTS The expression rate of ERalpha in patients with FIGO stage I endometrial carcinoma was more than that in stage II-IV(P = 0.005). The expression rate of ERRalpha in endometrial carcinoma patients at FIGO stage I was lower than that at stages II-IV(P = 0.007). The percentage of patients at FIGO stageI or with G1-2 or myometrial invasion < 1/2 in ERalpha (+) and ERRalpha (-) groups was higher than that in ERalpha (-) and ERRalpha (+) groups(P = 0.000, P = 0.031 and P = 0.022). CONCLUSION ERalpha may be a biomarker of good prognosis while ERRalpha may serve as a biomarker of poor prognosis in endometrial carcinoma. The combinative measure of ERalpha and ERRalpha may improve the prognostic value.
What problem does this paper attempt to address?